Presentation on theme: "Effects of Listing and Delisting in National Essential Medicine List on Utilization Patterns Sauwakon Ratanawijitrasin, PhD and Sanita Hirunrassamee, PhD."— Presentation transcript:
Effects of Listing and Delisting in National Essential Medicine List on Utilization Patterns Sauwakon Ratanawijitrasin, PhD and Sanita Hirunrassamee, PhD
Background pharmacological categoryGeneric NEML Lipid-regulating drugs Lipid-regulating drugs Simvastatin Atorvastatin Rosuvastatin Dugs affecting the renin-angiotensin system Enalapril maleate Losartan potassium Valsartan Drugs used in the control of epilepsy Sodium valproate Topiramate Levitriacetam Gabapentin Pregabapentin
Objective To examine the effects of NEML listing and delisting on the utilization patterns comparing: Delisted drugs with remaining or Added medicines non-essential medicines (NEM- not listed in both NEML editions) in the same pharmacological category NEML: National Essential Medicine List
Methodology 9 government hospitals 1.Statins 2.ACEIs 3.Anti- epileptics Segmented Regression Analysis of interrupted time series data OPD e-dispensing databases Statistics 3 groups of Medicine Data Source: Dispensing data collected for "Data management for systematic monitoring of drug utilization and policy project"--a collaboration between IMRTA and PharReD Foundation.
Methodology (cont.) Before NEML After 14 mo mo 24 months time-series data points
Utilization Patterns across Health Insurance Scheme
Conclusion NS No statistical significant changes in the utilization patterns of the listed, delisted and non-listed medicines occurred after the introduction of the 2008 NEML Sig. Discrepancies in utilization were found among patients in different health insurance systems. Ans. It appears that health insurance policy exerts greater influence on utilization patterns than essential medicine policy.
Acknowledgement: Institute of Medical Research Technology Assessment (IMRTA) and Pharmaceutical System Research & Development Foundation (PharReD Foundation)